-

Padraig McDonnell Assumes Agilent CEO Role

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE:A) today announced that Padraig McDonnell has assumed the role of Agilent CEO, effective immediately. His appointment is part of the company’s CEO transition plan announced Feb. 21. McDonnell is the fourth CEO in Agilent’s history and succeeds Mike McMullen, who will serve as an adviser until he retires Oct. 31.

“It’s an incredible honor to serve as CEO of this great company that impacts the world by advancing the quality of life,” McDonnell said. “I’m proud of how we forge partnerships with our customers to help them bring great science to life, and I’m excited to lead Agilent because of the possibilities that lie ahead for us.”

“Based on his proven record of success, we firmly believe Padraig McDonnell is the right choice to lead Agilent,” said Koh Boon Hwee, chairman of Agilent's Board of Directors. “We look forward to working with him to build on that success as CEO.”

Before being named CEO-elect in February, McDonnell, 52, had served as president of the Agilent CrossLab Group (ACG) since May 2020. His role leading ACG expanded in November 2021, when he was also named to lead the company’s commercial organization as chief commercial officer.

As President of ACG, McDonnell drove outstanding growth in Agilent's services business, with significant improvements in profitability and customer satisfaction. As chief commercial officer, he also led the transformation of the customer experience at Agilent by improving the end-to-end customer journey and customer lifetime value.

Prior to becoming ACG president, McDonnell was vice president and general manager of Agilent's Chemistries and Supplies Division, a role to which he was named in 2017. He has been in the analytical- and scientific-instrument industry for 26 years, starting his career with Agilent's predecessor Hewlett-Packard Co. in 1998.

“With Padraig at the helm, the future is bright for Agilent,” McMullen said. “His leadership skills, knowledge and customer focus will serve the company well for many years to come.”

For more information regarding Agilent’s new CEO, please visit the Agilent website.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.83 billion in fiscal 2023 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

Contacts

Media Contact:
Tom Beermann
+1 408-386-5892
tom.beermann@agilent.com

Investor Contact:
Parmeet Ahuja
+1 408-345-8948
parmeet_ahuja@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions

Contacts

Media Contact:
Tom Beermann
+1 408-386-5892
tom.beermann@agilent.com

Investor Contact:
Parmeet Ahuja
+1 408-345-8948
parmeet_ahuja@agilent.com

Social Media Profiles
More News From Agilent Technologies Inc.

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved companion diagnostic indicated to aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. PD-L1 IHC 22C3 pharm...

Agilent Announces Cash Dividend of 25.5 Cents per Share

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced a quarterly dividend of 25.5 cents per share of common stock. The quarterly dividend will be paid on April 22, 2026, to all shareholders of record as of the close of business on March 31, 2026. The timing and amounts of future dividends are subject to the determination and approval of Agilent’s board of directors. About Agilent Technologies Agilent Technologies, Inc. (NYSE: A) is a global leader in analyti...

Agilent Presents Boehringer Ingelheim With Inaugural 2025 Instrument Trade‑In Impact Award

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Boehringer Ingelheim has been selected as the winner of Agilent’s inaugural Instrument Trade‑In Impact Award, recognizing exceptional sustainability leadership demonstrated through their participation in Agilent’s trade‑in and buyback program. The annual award honors the global partner that achieves the highest sustainability impact by diverting end‑of‑life laboratory instruments from landfill and con...
Back to Newsroom